Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization

Microvascular Research

Volumn 74, Issue 2-3, 2007, Pages 72-84

  Fukumura, Dai ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acidosis; Angiogenesis; Hypoxia; Interstitial fluid pressure; Lymphangiogenesis; Metastasis; Microenvironment; Stromal cells; Tumor; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BEVACIZUMAB; BLEOMYCIN; DOXORUBICIN; INTERLEUKIN 8; MITOXANTRONE; MONOCLONAL ANTIBODY DC101; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SU 11657; THALIDOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ZINOSTATIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD FLOW; BLOOD VESSEL; BLOOD VESSEL FUNCTION; BREAST CANCER; CANCER RADIOTHERAPY; COLON CANCER; GENE EXPRESSION; GLIOMA; HUMAN; HYPOXIA; MELANOMA; MICROVASCULATURE; PATHOPHYSIOLOGY; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW; TISSUE PRESSURE; TUMOR GROWTH; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 35748970483     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2007.05.003     Document Type: Review

References (97)

1. Alitalo K., et al. Lymphangiogenesis in development and human disease. Nature 438 (2005) 946-953
2. Ansiaux R., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin. Cancer Res. 11 (2005) 743-750
3. Batchelor T.T., et al. AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
4. Boardman K.C., and Swartz M.A. Interstitial flow as a guide for lymphangiogenesis. Circ. Res. 92 (2003) 801-808
5. Boucher Y., and Jain R.K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 52 (1992) 5110-5114
6. Boucher Y., et al. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50 (1990) 4478-4484
7. Brown J.M. The hypoxic cell: a target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 59 (1999) 5863-5870
8. Brown J.M., and Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58 (1998) 1408-1416
9. Brown E.B., et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat. Med. 7 (2001) 1069
10. Brown E.B., et al. In vivo measurement of gene expression, angiogenesis, and physiological function in tumors using multiphoton laser scanning microscopy. Nat. Med. 7 (2001) 864-868
11. Chang Y.S., et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14608-14613
12. de Visser K.E., et al. Paradoxical roles of the immune system during cancer development. Nat. Rev., Cancer 6 (2006) 24-37
13. Dellian M., et al. Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am. J. Pathol. 149 (1996) 59-72
14. Dewhirst M.W. Concepts of oxygen transport at the microcirculatory level. Semin. Radiat. Oncol. 8 (1998) 143-150
15. di Tomaso E., et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res. 65 (2005) 5740-5749
16. DiResta G.R., et al. "Artificial lymphatic system": a new approach to reduce interstitial hypertension and increase blood flow, pH and pO(2) in solid tumors. Ann. Biomed. Eng. 28 (2000) 543-555
17. Duda D.G., et al. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat. Protocols 2 (2007) 805-810
18. Dvorak H.F., et al. Tumor architecture and targeted delivery. In: Abrams P.G., and Fritzberg A.R. (Eds). Radioimmunotherapy of Cancer (2002), Marcel Dekker, Inc., New York 107-135
19. Elenbaas B., and Weinberg R.A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264 (2001) 169-184
20. Erler J.T., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006) 1222-1226
21. Fidler I.J. Angiogenic heterogenity: regulation of neoplastic angiogenesis by the organ microenvironment. J. Natl. Cancer Inst. 93 (2001) 1040-1041
22. Folkman J. Tumor angiogenesis. In: Holland J.F., et al. (Ed). Cancer Medicine (2000), B.C. Decker Inc., Ontario, Canada 132-152
23. Fukumura D. Role of microenvironment on gene expression, angiogenesis and microvascular functions in tumors. In: Meadows G.G. (Ed). Integration/Interaction of Oncologic Growth vol. 15 (2005), Springer Science, Dordrecht 23-36
24. Fukumura, D., Jain, R.K., in press. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. Journal of Cellular Biochemistry. doi:10.1002/jcb.21187.
25. Fukumura D., et al. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am. J. Pathol. 151 (1997) 679-688
26. Fukumura D., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94 (1998) 715-725
27. Fukumura D., et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61 (2001) 6020-6024
28. Garcia-Barros M., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
29. Gerlowski L.E., and Jain R.K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31 (1986) 288-305
30. Gohongi T., et al. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor b1. Nat. Med. 5 (1999) 1203-1208
31. Gupta P.B., et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 67 (2007) 2062-2071
32. Gutman M., et al. Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res. 55 (1995) 2470-2475
33. Hagendoorn J., et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 66 (2006) 3360-3364
34. Hansen-Algenstaedt N., et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockage, hormone ablation, and chemotherapy. Cancer Res. 60 (2000) 4556-4560
35. Harris A.L. Hypoxia: a key regulatory factor in tumour growth. Nat. Rev., Cancer 2 (2002) 38-47
36. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3 (1997) 177-182
37. Helmlinger G., et al. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res. 8 (2002) 1284-1291
38. Hobbs S.K., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4607-4612
39. Hoshida T., et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 66 (2006) 8065-8075
40. Huber P.E., et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 65 (2005) 3643-3655
41. Isaka N., et al. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res. 64 (2004) 4400-4404
42. Izumi Y., et al. Herceptin acts as an anti-angiogenic cocktail. Nature 416 (2002) 279-280
43. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6 (1987) 559-593
44. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res. 48 (1988) 2641-2658
45. Jain R.K. The Eugene M. Landis Award Lecture. Delivery of molecular and cellular medicine to solid tumors. Microcirculation 4 (1997) 1-23
46. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7 (2001) 987-989
47. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. (2003)
48. Jain R.K. Vascular and interstitial biology of tumors. In: Abeleff M., et al. (Ed). Clinical Oncology (2004), Elsevier, Philadelphia 153-172
49. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
50. Jain, R.K., et al., 1995. Method for locating tumors prior to needle biopsy. USA patent No. 5,396,897.
51. Jain R.K., et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10820-10825
52. Jain R.K., et al. Dissecting tumor pathophysiology using intravital microscopy. Nat. Rev., Cancer 2 (2002) 266-276
53. Jain R.K., et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3 (2006) 24-40
54. Jain R.K., et al. Effect of vascular normalization by antiangiogenic therapy on inerstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67 (2007) 2729-2735
55. Kashiwagi S., et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115 (2005) 1816-1827
56. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev., Cancer 4 (2004) 423-436
57. Kozin S.V., et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61 (2001) 39-44
58. Krogh A. The Anantomy and Physiology of Capillaries (1922), Yale University Press, New York
59. Lee C.G., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60 (2000) 5565-5570
60. Leu A.J., et al. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 60 (2000) 4324-4327
61. Li G., et al. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 22 (2003) 3162-3171
62. Liotta L.A., and Kohn E.C. The microenvironment of the tumour-host interface. Nature 411 (2001) 375-379
63. Martin G.R., and Jain R.K. Fluorescence ratio imaging measurement of pH gradients: calibration and application in normal and tumor tissues. Microvasc. Res. 46 (1993) 216-230
64. McDonald D.M., and Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat. Med. 9 (2003) 713-725
65. Monsky W.L., et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 59 (1999) 4129-4135
66. Monsky W.L., et al. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad vs. cranial tumors. Clin. Cancer Res. 8 (2002) 1008-1013
67. Netti P.A., et al. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug-delivery. Cancer Res. 55 (1995) 5451-5458
68. Noel A., et al. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br. J. Cancer 68 (1993) 909-915
69. Orimo A., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 (2005) 335-348
70. Padera T.P., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296 (2002) 1883-1886
71. Padera T.P., et al. Pathology: cancer cells compress intratumour vessels. Nature 427 (2004) 695
72. Pennacchietti S., et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003) 347-361
73. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev., Cancer 4 (2004) 71-78
74. Pouyssegur J., et al. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
75. Rofstad E.K., et al. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 66 (2006) 6699-6707
76. Roose T., et al. Solid stress generated by spheroid growth estimated using a linear poroelasticity model. Microvasc. Res. 66 (2003) 204-212
77. Ruiter D.J., et al. Tumour metastasis: is tissue an issue?. Lancet Oncol. 2 (2001) 109-112
78. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev., Cancer 3 (2003) 721-732
79. Singh R.K., et al. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am. J. Pathol. 145 (1994) 365-374
80. Tatum J.L., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 82 (2006) 699-757
81. Tlsty T.D. Stromal cells can contribute oncogenic signals. Cancer Biol. 11 (2001) 97-104
82. Tong R.T., et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004) 3731-3736
83. Torres-Filho I.P., et al. Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 2081-2085
84. Tsuzuki Y., et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia inducible factor-1α → Hypoxia response element → VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 60 (2000) 6248-6252
85. Tsuzuki Y., et al. Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation. Lab. Invest. 81 (2001) 1439-1452
86. Vosseler S., et al. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 65 (2005) 1294-1305
87. Vukovic V., and Tannock I.F. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br. J. Cancer 75 (1997) 1167-1172
88. Weinberg R.A. The Biology of Cancer (2006), Garland Science Publishing, New York
89. Wildiers H., et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88 (2003) 1979-1986
90. Willett C.G., et al. Direct evidence that the anti-VEGF antibody Bevacizumab has anti-vascular effects in human rectal cancer. Nat. Med. 10 (2004) 145-147
91. Willett C.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for Bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 23 (2005) 8136-8139
92. Winkler F., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1 and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
93. Xu L., et al. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway-Mechanism of low pH-induced VEGF. J. Biol. Chem. 277 (2002) 11368-11374
94. Xu L., et al. Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3′-kinase signaling pathways contributes to expression of interleukin-8 in human ovarian carcinoma cells. Clin. Cancer Res. 10 (2004) 701-707
95. Yuan F., et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54 (1994) 3352-3356
96. Yuan F., et al. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 54 (1994) 4564-4568
97. Yuan F., et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14765-14770